Early drug study for advanced cancers that have limited options
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Hormones & metabolism, Immune system & allergy, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer has spread (metastatic) or cannot be surgically removed (unresectable), and you’ve had standard treatment or can’t get it.
- Your body is strong enough for study treatment (ECOG performance status 0 or 1).
- You can provide recent tumor tissue for biopsy (and for some groups, a lymph node).
- You have enough blood and organ function based on lab tests.
- You can follow study rules and take part for the full study; you must sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.